O Neil Global Advisors Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 30.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,535 shares of the company’s stock after selling 663 shares […]
GW&K Investment Management LLC lessened its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 3.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 535,962 shares of the company’s stock after selling 18,829 shares during the period. […]
Allegheny Financial Group LTD purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,698 shares of the company’s stock, valued at approximately $224,000. Several other hedge funds and other institutional investors have also […]
Brown Advisory Inc. raised its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,113,413 shares of the company’s stock after buying an additional 23,831 shares during the quarter. Brown […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) and Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, earnings and analyst recommendations. Profitability This table compares Neurocrine Biosciences and Jasper […]